Impact on Healthcare

SAVING LIVES
IN RESISTANT TIMES

Antimicrobial Resistance (AMR) is the silent pandemic that threatens our global healthcare systems and well-being in an unprecedented manner. At BioVersys, we fight AMR using innovation to save lives and improve patient outcomes.

Logo
The silent pandemic…

The global impact of Antimicrobial Resistance on people is huge

1.27 million

 casualties directly linked to drug resistant infection

10 million

annual deaths by 2050 if no action taken

13.5 US$ billion

annual financial loss in US & EU due to hospital infections

Identifying unmet medical needs

Making people’s lives better

In March 1942, Anne Miller was near death. Infectious germs had made their way into her bloodstream. Doctors administered an experimental drug to her – Penicillin – and she recovered. She became the first person in the world to be saved by an antibiotic. Unfortunately, germs like the one that infected Anne Miller are becoming or have become resistant to antibiotics. Over the last few decades, we have seen limited to no progress in the introduction of new antibiotics. This is a ticking time bomb that threatens the world’s healthcare systems and endanger lives.

Mann arbeitet im Labor
Rich and diverse pipeline

Impactful solutions for AMR

Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3
Partners

BV100 – novel MoA
Serious hospital infections -
A. baumannii

Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3

BV100 – novel MoA
Serious hospital infections -
A. baumannii

  • 0%

Alpibectir – novel potentiator MoA
MDR-TB
TB Meningitis (TBM)

Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3

Alpibectir – novel potentiator MoA
MDR-TB
TB Meningitis (TBM)

  • 0%

BV200 – novel anti-virulence MoA
S. aureus

Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3

BV200 – novel anti-virulence MoA
S. aureus

  • 0%
innosuisse logo supported swiss accelerator innovation project rgb en

BV500 - novel series
NTM infections

Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3

BV500 - novel series
NTM infections

  • 0%

BV Discovery

Lead optimization
Preclinical
Phase 1
Phase 2
Phase 3

BV Discovery

  • 0%
youtube-video-thumbnail

BioVersys featured in a recent video highlighting the fight against AMR in Basel.

About us

Who we are

We are a passionate team, fighting against bacterial infections by focusing on research and development of small molecules that work by novel modes of action and against novel targets. BioVersys is an award winning privately-owned Swiss pharmaceutical company headquartered in Basel, Switzerland.

Scroll to Top